Primary Myelofibrosis
A blood cancer where the bone marrow becomes scarred and fibrotic, forcing the spleen and liver to take over blood production, resulting in profound anemia and a massively enlarged spleen.
Emergency Management: Acute splenic rupture (presents with sudden, severe abdominal pain and hypovolemic shock) requiring emergent exploratory laparotomy and splenectomy.
Primary Myelofibrosis (PMF) is a rare, clonal Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes and granulocytes in the bone marrow, accompanied by reactive deposition of fibrous connective tissue. This fibrosis displaces normal hematopoiesis, leading to severe anemia, marked extramedullary hematopoiesis (predominantly in the spleen and liver), and debilitating constitutional symptoms.
Detailed Overview
PMF is driven by acquired somatic mutations in JAK2, CALR, or MPL genes, which result in constitutive activation of the JAK-STAT signaling pathway. The malignant megakaryocytes release cytokines (like TGF-beta, PDGF, and FGF) that stimulate benign bone marrow fibroblasts to produce excessive collagen. As the bone marrow space is obliterated, hematopoiesis shifts to the spleen and liver, causing massive organomegaly. PMF has the worst prognosis among the classic MPNs, with a high risk of progression to acute myeloid leukemia (AML).
Epidemiology & Demographics
Incidence is roughly 1-1.5 cases per 100,000 annually. It is primarily a disease of older adults, with a median age at diagnosis of 65-70 years. Slight male predominance.
Etiological Mechanism
Clonal stem cell disorder driven by driver mutations: JAK2 V617F (~60% of cases), CALR (~25%), and MPL (~5%). About 10% are 'triple-negative'.
Primary Causes
The fundamental cause is somatic genetic mutations activating the JAK-STAT pathway. The marrow fibrosis is not a malignant process itself, but a reactive response to profibrotic cytokines secreted by the malignant megakaryocyte clone.
Mutant hematopoietic stem cells proliferate autonomously. The megakaryocytes are dysplastic and produce elevated levels of inflammatory and fibrogenic cytokines (TGF-beta, bFGF, VEGF). These cytokines stimulate polyclonal fibroblasts to deposit reticulin and later collagen fibrosis in the marrow. This creates a hostile marrow environment (osteosclerosis and neoangiogenesis). To compensate for failing marrow production, hematopoietic stem cells migrate to extramedullary sites (spleen, liver, sometimes lymph nodes), causing profound extramedullary hematopoiesis (EMH) and massive splenomegaly. The EMH is often ineffective, leading to progressive cytopenias.
Diagnostic Criteria & Guidelines
WHO criteria require 3 major + at least 1 minor criteria. Major: 1) Megakaryocytic proliferation and atypia with reticulin/collagen fibrosis, 2) Not meeting criteria for CML, PV, MDS, 3) Presence of JAK2, CALR, or MPL mutation. Minor: Anemia not attributed to another condition, palpable splenomegaly, elevated LDH, leukoerythroblastosis.
Symptomatic treatment focused on splenomegaly and systemic symptoms: JAK1/JAK2 Inhibitors (Ruxolitinib starting at 15-20 mg PO BID based on platelets). Ruxolitinib dramatically shrinks the spleen and improves symptoms but does not reverse marrow fibrosis or cure the disease. For anemia: Erythropoiesis-stimulating agents (ESAs) or Danazol 200-600 mg/day.
Second-Line & Adjunctive Therapy
Alternative JAK inhibitors for patients who fail Ruxolitinib or have severe cytopenias: Fedratinib 400 mg daily, Pacritinib 200 mg BID (specifically for severe thrombocytopenia <50k), or Momelotinib. The only curative therapy is Allogeneic Stem Cell Transplantation (allo-HSCT), reserved for younger, fit patients with intermediate-2 or high-risk disease.
Surgical & Procedural Management
Splenectomy is highly controversial and reserved for refractory, massive splenomegaly causing severe mechanical pain, portal hypertension, or frequent transfusions, but it carries a high perioperative mortality (up to 10%) and risk of extreme reactive hepatomegaly.
Patient Counseling & Advice
Explain that the disease is a chronic blood cancer. While JAK inhibitors can dramatically improve quality of life and shrink the spleen, they are not a cure. Discuss the signs of disease progression, particularly worsening fatigue, bleeding, or rapidly enlarging spleen. For younger patients, refer early to a transplant center.
Follow-Up & Monitoring Schedule
Monthly visits initially to titrate JAK inhibitors and monitor CBC. Long-term monitoring every 3 months. Calculate DIPSS (Dynamic International Prognostic Scoring System) score annually to assess transplant eligibility.
Preventive Strategies
No known primary prevention.
Highly variable based on risk scores (DIPSS). Low-risk patients may survive >15 years. High-risk patients have a median survival of 1-3 years. Allo-HSCT offers a roughly 50% chance of long-term cure but has significant transplant-related mortality.